Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions involving its shares by individuals in managerial positions, reflecting ongoing movements within the company. The biotechnology firm, based in Copenhagen, specializes in peptide-based medicines, with over 10 drug candidates currently in clinical development. Among its marketed products are V-Go® and Zegalogue®. Zealand Pharma's collaborations with Boehringer Ingelheim and AstraZeneca may enhance its market reach.
Further details can be found in the attachments included in the release.
- Clinical development of over 10 drug candidates.
- Two drugs have successfully reached the market.
- Collaborations with Boehringer Ingelheim and AstraZeneca may expand market access.
- None.
Company announcement – No. 2 / 2022
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Copenhagen, DK and Boston, MA, May 31, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
Please see the attached files.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In the US Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com
Attachments
FAQ
What does Zealand Pharma (ZEAL) focus on?
What are some products marketed by Zealand Pharma?
What recent transactions occurred involving Zealand Pharma (ZEAL) shares?
How many drug candidates has Zealand Pharma developed?
Which companies has Zealand Pharma partnered with?
